What are the implications of the lack of evidence for the use of ezetimibe for primary prevention?
The lack of evidence for the use of ezetimibe for primary prevention has several implications. Firstly, providers may not be able to confidently prescribe ezetimibe to patients who cannot tolerate statins for primary prevention. Additionally, negative press coverage and patient apprehension towards statins limits the options available for primary prevention. Finally, the FDA only approved PCSK9 inhibitors for primary prevention in FH based solely on the effect of lipid parameters in this population, but none of the studies were designed to measure CV outcomes.